REN and congestive heart failure: Renin‐angiotensin‐system blockers (RASB) are cornerstones in the treatment of chronic heart failure with reduced left ventricular ejection fraction, leading to a reduction in morbidity and mortality.1, 2, 3, 4 However, there remains some ambiguity whether RASB should be continued during the treatment of patients with acute decompensated heart failure (ADHF) who develop hypotension or worsening renal function.